絞り込み

16555

広告

Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.

著者 McHorney CA , Peterson ED , Ashton V , Laliberté F , Crivera C , Germain G , Sheikh N , Schein J , Lefebvre P
Curr Med Res Opin.2018 Sep 28 ; ():1-21.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (37view , 0users)

Full Text Sources

Miscellaneous

To estimate the real-world (RW) impact of adherence to once-daily (QD: rivaroxaban and edoxaban) and twice-daily (BID: apixaban and dabigatran) non-vitamin K antagonist (NOACs) on the risk of stroke and major bleeding (MB) among non-valvular atrial fibrillation (NVAF) patients.
PMID: 30265159 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード